Taiho Ventures

Normunity is a biotechnology company focused on developing a new class of precision immuno-oncology medicines known as immune normalizers. These innovative therapies aim to restore the body's natural immune response against cancer by targeting novel mechanisms that disrupt immune function. Normunity collaborates closely with the lab of Dr. Lieping Chen at Yale School of Medicine, leveraging proprietary discovery platforms to explore complex interactions between cancer and the immune system. The company's emerging pipeline includes drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune activity in cancer patients. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of more effective therapies.

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Anavo Therapeutics is a pioneering company focused on drugging phosphatases, a category of targets that has been deemed undruggable for many years. By leveraging world-class scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo aims to develop innovative therapeutic programs, particularly in oncology. The company is advancing multiple first-in-class therapies and seeks to establish a robust pipeline across various indications through strategic partnerships. Anavo's work in this area seeks to unlock the potential of phosphatase-targeted allosteric modulators, offering new avenues for treatment in diseases where traditional approaches have fallen short.

Cellvie is a biotechnology company focused on developing cell-derived medicines that harness the therapeutic potential of mitochondria, the essential organelles responsible for energy production in cells. The company specializes in innovative techniques for the transplantation of viable mitochondria into compromised cells, aiming to restore their energy metabolism and function. This approach addresses mitochondrial dysfunction associated with various medical conditions, including heart disease, stroke, diabetes, Parkinson's, and Alzheimer's. By employing proprietary preparation and delivery methods, Cellvie seeks to interrupt the damaging cascade of events caused by ischemia-reperfusion injury, ultimately enhancing cellular performance and improving patient outcomes.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Normunity is a biotechnology company focused on developing a new class of precision immuno-oncology medicines known as immune normalizers. These innovative therapies aim to restore the body's natural immune response against cancer by targeting novel mechanisms that disrupt immune function. Normunity collaborates closely with the lab of Dr. Lieping Chen at Yale School of Medicine, leveraging proprietary discovery platforms to explore complex interactions between cancer and the immune system. The company's emerging pipeline includes drug programs designed to address the exclusion of T-cells from immune-sensitive tumors and other factors that impede normal immune activity in cancer patients. Normunity operates from locations in Boston, Massachusetts, and West Haven, Connecticut.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

MAKUKU is a retail platform specializing in mother-infant products, offering a diverse range of items including baby care products, formula milk, supplementary meals, children's clothing, personal care items, and cotton goods. The company operates through various channels, including its mobile app, an online mall on WeChat, and established platforms like Tmall and JD. In addition to its online presence, MAKUKU maintains offline locations to serve its customers. By combining multiple retail features and brands, MAKUKU aims to provide a comprehensive shopping experience for mothers and infants.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Anavo Therapeutics is a pioneering company focused on drugging phosphatases, a category of targets that has been deemed undruggable for many years. By leveraging world-class scientific expertise in phosphatase-driven disease biology and drug discovery, Anavo aims to develop innovative therapeutic programs, particularly in oncology. The company is advancing multiple first-in-class therapies and seeks to establish a robust pipeline across various indications through strategic partnerships. Anavo's work in this area seeks to unlock the potential of phosphatase-targeted allosteric modulators, offering new avenues for treatment in diseases where traditional approaches have fallen short.

Orna Therapeutics, founded in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts, is a biotechnology company specializing in the development of fully engineered circular RNA therapeutics. The company's proprietary platform combines innovative technology to create circular RNAs that drive protein expression, coupled with validated delivery solutions. This approach aims to simplify production, enhance formula stability, and improve protein expression for treating various diseases.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

PACT Pharma, Inc. is a biotechnology company focused on developing personalized cell-based therapies for cancer treatment. The company specializes in neoantigen-specific adoptive T-cell therapies aimed at solid tumors. Its innovative platform utilizes bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying candidate neoantigen peptides that stimulate robust antitumor T-cell responses. By pinpointing neo-epitopes unique to each patient's cancer, PACT Pharma enables the engineering of autologous T cells that specifically target and eradicate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is dedicated to advancing personalized medicine in oncology.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies to combat cancer by overcoming resistance mechanisms. The company's lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which plays a significant role in resistance to various cancer treatments across multiple solid tumors. Another key candidate, ORIC-533, is an orally bioavailable inhibitor of CD73, targeting a critical pathway in the adenosine metabolism that contributes to resistance against chemotherapy and immunotherapy. Additionally, ORIC is working on a pipeline of precision medicines aimed at addressing other cancer resistance mechanisms. Founded in 2014 and headquartered in South San Francisco, California, ORIC Pharmaceuticals leverages the expertise of its scientific founders, who have extensive backgrounds in cancer research and target discovery.

Breakpoint Therapeutics GmbH, based in Hamburg, Germany, is dedicated to the discovery and development of innovative anti-cancer drugs. The company focuses on targeting the DNA damage response (DDR) in cancer cells, aiming to create first-in-class oncology drugs that disrupt DNA repair mechanisms and replication stress tolerance pathways. By developing therapeutics that complement existing treatments, such as PARP inhibitors, Breakpoint Therapeutics seeks to address the challenges posed by therapy-resistant cancers, ultimately striving to improve patient outcomes in oncology.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

NextCure, Inc. is a clinical-stage biopharmaceutical company based in Beltsville, Maryland, that focuses on discovering and developing novel immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is currently undergoing Phase 2 clinical trials for advanced or metastatic solid tumors. Additionally, NextCure is developing NC410, designed to inhibit immune suppression through the modulation of a specific immune receptor. The company is also advancing other product candidates, including LNCB74, an antibody-drug conjugate targeting B7-H4, and is exploring additional immunomodulatory molecules in preclinical stages. NextCure has established collaborations with Yale University for licensing and with Eli Lilly and Company for research and development. Founded in 2015, the company leverages proprietary platforms to identify biologically relevant targets in its pursuit of first-in-class immunotherapy solutions.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapies to combat cancer by overcoming resistance mechanisms. The company's lead product candidate, ORIC-101, is a small molecule antagonist of the glucocorticoid receptor, which plays a significant role in resistance to various cancer treatments across multiple solid tumors. Another key candidate, ORIC-533, is an orally bioavailable inhibitor of CD73, targeting a critical pathway in the adenosine metabolism that contributes to resistance against chemotherapy and immunotherapy. Additionally, ORIC is working on a pipeline of precision medicines aimed at addressing other cancer resistance mechanisms. Founded in 2014 and headquartered in South San Francisco, California, ORIC Pharmaceuticals leverages the expertise of its scientific founders, who have extensive backgrounds in cancer research and target discovery.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative immunotherapies for cancer treatment. Founded in 2015, the company leverages insights from immunology to create novel therapies targeting the ATP-adenosine pathway, a critical driver of immunosuppression in the tumor microenvironment. Arcus has a diverse product pipeline featuring several candidates, including Etrumadenant (AB928), a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials; Zimberelimab, an anti-PD-1 monoclonal antibody in Phase Ib trials; and AB154, an anti-TIGIT monoclonal antibody in Phase 2 development for first-line metastatic non-small cell lung cancer. Additionally, AB680, a small-molecule CD73 inhibitor, is undergoing Phase 1/1b studies for the treatment of first-line metastatic pancreatic cancer. The company collaborates with other organizations, including AstraZeneca and Strata Oncology, to advance its clinical programs.